High Court dismisses generic manufacturers’ bid to be included in NHS price negotiations

The British Generic Manufacturers Association had argued that it should have full participation in negotiations over a new branded medicines tax scheme because branded generics and biosimilars make up almost half of those in the current scheme.
piles of tablets in blister packs
The BGMA had sought judicial review after being offered 'observer status' in talks on a new tax scheme for branded medicines manufacturers

Shutterstock.com

The High Court has dismissed a judicial review brought by the British Generic Manufacturers Association (BGMA) against a government decision to exclude it from being fully involved in negotiations over a new tax scheme for branded medicines sold to the NHS.

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Last updated